RE:RE:"His exit could cause “reverberations” through the industry"It's just a little reality window into what any smaller pharma is up against.
And why we pay all the suits to play the game. Just another hurdle built into the system to protect big pharma from competition, and not one which is easy to quantify much less mitigate.